Jasper Therapeutics/JSPR

$21.84

5%
-
1D1W1MYTD1YMAX

About Jasper Therapeutics

Jasper Therapeutics, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of therapeutic agents for diseases, such as Chronic Spontaneous Urticaria (CSU), Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS) and conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The Company's lead product candidate, briquilimab, is in clinical development as a therapeutic antibody that targets mast and stem cells in various diseases and as a conditioning agent to clear hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. The Company is also developing engineered hematopoietic stem cell product candidates reprogrammed using mRNA delivery (mRNA stem cell platform) and gene editing.

Ticker

JSPR

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ronald Martell

Employees

35

Headquarters

Redwood city, United States

JSPR Metrics

BasicAdvanced
$303.29M
Market cap
-
P/E ratio
-$8.29
EPS
2.15
Beta
-
Dividend rate

What the Analysts think about JSPR

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 2 analysts.
209.07% upside
High $80.00
Low $55.00
$21.84
Current price
$67.50
Average price target

JSPR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-17.5M
9.38%
Profit margin
0%
-

JSPR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.06%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$3.60
-$1.60
-$1.50
-$1.60
-
Expected
-$3.60
-$1.62
-$1.50
-$1.55
-$1.62
Surprise
0%
-1.48%
0.13%
3.06%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Jasper Therapeutics stock

Buy or sell Jasper Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing